AU2020295793B2 - Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication - Google Patents

Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication Download PDF

Info

Publication number
AU2020295793B2
AU2020295793B2 AU2020295793A AU2020295793A AU2020295793B2 AU 2020295793 B2 AU2020295793 B2 AU 2020295793B2 AU 2020295793 A AU2020295793 A AU 2020295793A AU 2020295793 A AU2020295793 A AU 2020295793A AU 2020295793 B2 AU2020295793 B2 AU 2020295793B2
Authority
AU
Australia
Prior art keywords
mmol
stirred
methyl
compound
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020295793A
Other languages
English (en)
Other versions
AU2020295793A1 (en
Inventor
Eric P. Gillis
Christiana Iwuagwu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71738195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020295793(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of AU2020295793A1 publication Critical patent/AU2020295793A1/en
Application granted granted Critical
Publication of AU2020295793B2 publication Critical patent/AU2020295793B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020295793A 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication Active AU2020295793B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
AU2020295793A1 AU2020295793A1 (en) 2022-01-20
AU2020295793B2 true AU2020295793B2 (en) 2023-07-06

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020295793A Active AU2020295793B2 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Country Status (33)

Country Link
US (2) US12129255B2 (cg-RX-API-DMAC7.html)
EP (1) EP3986561B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102932817B1 (cg-RX-API-DMAC7.html)
CN (2) CN114245795B (cg-RX-API-DMAC7.html)
AR (1) AR119174A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020295793B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025655A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021003388A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017479A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210664A (cg-RX-API-DMAC7.html)
DK (1) DK3986561T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974541T3 (cg-RX-API-DMAC7.html)
FI (1) FI3986561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240501T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065762T2 (cg-RX-API-DMAC7.html)
IL (1) IL288750B2 (cg-RX-API-DMAC7.html)
LT (1) LT3986561T (cg-RX-API-DMAC7.html)
MA (1) MA56526B1 (cg-RX-API-DMAC7.html)
MD (1) MD3986561T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021016149A (cg-RX-API-DMAC7.html)
MY (1) MY206712A (cg-RX-API-DMAC7.html)
PE (1) PE20220510A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553180A1 (cg-RX-API-DMAC7.html)
PL (1) PL3986561T3 (cg-RX-API-DMAC7.html)
PT (1) PT3986561T (cg-RX-API-DMAC7.html)
RS (1) RS65304B1 (cg-RX-API-DMAC7.html)
SI (1) SI3986561T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400153T1 (cg-RX-API-DMAC7.html)
TW (1) TWI850403B (cg-RX-API-DMAC7.html)
UA (1) UA128967C2 (cg-RX-API-DMAC7.html)
UY (1) UY38755A (cg-RX-API-DMAC7.html)
WO (1) WO2020254985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
AU2020358156B2 (en) * 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364279A1 (en) 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) * 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
HRP20240501T1 (hr) 2024-07-05
JP2022537047A (ja) 2022-08-23
UA128967C2 (uk) 2024-12-11
MX2021016149A (es) 2022-05-18
MA56526B1 (fr) 2024-05-31
MD3986561T2 (ro) 2024-06-30
PH12021553180A1 (en) 2022-11-07
RS65304B1 (sr) 2024-04-30
AU2020295793A1 (en) 2022-01-20
PE20220510A1 (es) 2022-04-07
MA56526A (fr) 2022-04-27
UY38755A (es) 2020-11-30
EP3986561A1 (en) 2022-04-27
CN119039288A (zh) 2024-11-29
LT3986561T (lt) 2024-04-25
TWI850403B (zh) 2024-08-01
WO2020254985A1 (en) 2020-12-24
SI3986561T1 (sl) 2024-04-30
IL288750B1 (en) 2024-12-01
PT3986561T (pt) 2024-03-15
CO2021017479A2 (es) 2022-04-19
US20210323967A1 (en) 2021-10-21
ES2974541T3 (es) 2024-06-27
US12129255B2 (en) 2024-10-29
KR102932817B1 (ko) 2026-03-04
IL288750B2 (en) 2025-04-01
IL288750A (en) 2022-02-01
TW202115055A (zh) 2021-04-16
EP3986561B1 (en) 2024-02-14
CR20210664A (es) 2022-01-21
JP7628512B2 (ja) 2025-02-10
CN114245795B (zh) 2024-08-06
BR112021025655A2 (pt) 2022-02-01
AR119174A1 (es) 2021-12-01
US20250019383A1 (en) 2025-01-16
HUE065762T2 (hu) 2024-06-28
DK3986561T3 (da) 2024-03-04
SMT202400153T1 (it) 2024-05-14
CA3143136A1 (en) 2020-12-24
CL2021003388A1 (es) 2022-09-30
CN114245795A (zh) 2022-03-25
KR20220024608A (ko) 2022-03-03
MY206712A (en) 2025-01-03
PL3986561T3 (pl) 2024-06-10
FI3986561T3 (fi) 2024-05-02

Similar Documents

Publication Publication Date Title
US20250019383A1 (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EP3917930B1 (en) Inhibitors of human immunodeficiency virus replication
AU2021256166B2 (en) Inhibitors of human immunodeficiency virus replication
AU2024201719A1 (en) Inhibitors of human immunodeficiency virus replication
US20230106880A1 (en) Inhibitors of human immunodeficiency virus replication
CA3143136C (en) Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40066649B (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
HK40066649A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CA3173866A1 (en) Inhibitors of human immunodeficiency virus replication
BR122024007306A2 (pt) Composição farmacêutica que compreende o composto da fórmula ia, fórmula ib, fórmula ic ou fórmula id e uso da mesma para tratamento de infecção por hiv

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)